IP Library › Granted Patent US 12,478,667
Granted Patent B2
US 12,478,667 · App. 18/353,421 · Granted Nov 25, 2025

Vaccines for recurrent respiratory papillomatosis and methods of using the same

Inventors: Stephanie Ramos (Santee, CA); Jewell Walters (Poway, CA); Jian Yan (Wallingford, PA); Anna Slager (Lansdale, PA); Charles Reed (Souderton, PA); Kate Broderick (San Diego, CA)
Assignee: Inovio Pharmaceuticals, Inc.
A61K39/12C07K14/025A61K2039/5254A61K2039/54A61K2039/55538
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,478,667
App. No.
18/353,421
Granted
Nov 25, 2025
Kind
B2
Abstract

Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and/or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.

Claims (56)

1 . A nucleic acid molecule comprising a nucleic acid sequence encoding a human papillomavirus 11 (HPV11) E6 antigen, a nucleic acid sequence encoding a HPV11 E7 antigen, a nucleic acid sequence encoding a human papillomavirus 6 (HPV6) E6 antigen, and a nucleic acid sequence encoding a HPV6 E7 antigen, wherein:

the HPV11 E6 antigen comprises residues 1-149 of SEQ ID NO: 1 or an amino acid sequence having at least 99% identity to residues 1-149 of SEQ ID NO: 1,

the HPV11 E7 antigen comprises residues 179-275 of SEQ ID NO: 1 or an amino acid sequence having at least 99% identity to residues 179-275 of SEQ ID NO: 1,

the HPV6 E6 antigen comprises residues 305-453 of SEQ ID NO: 1 or an amino acid sequence having at least 99% identity to residues 305-453 of SEQ ID NO: 1, and

the HPV6 E7 antigen comprises residues 483-579 of SEQ ID NO: 1 or an amino acid sequence having at least 99% identity to residues 483-579 of SEQ ID NO: 1; and

wherein:

the nucleic acid sequence encoding a HPV11 E6 antigen comprises nucleotides 1-447 of SEQ ID NO: 2 or a nucleic acid sequence having at least 99% identity to nucleotides 1-447 of SEQ ID NO: 2,

the nucleic acid sequence encoding a HPV11 E7 antigen comprises nucleotides 535-825 of SEQ ID NO: 2 or a nucleic acid sequence having at least 99% identity to nucleotides 535-825 of SEQ ID NO: 2,

the nucleic acid sequence encoding a HPV6 E6 antigen comprises nucleotides 913-1359 of SEQ ID NO: 2 or a nucleic acid sequence having at least 99% identity to nucleotides 913-1359 of SEQ ID NO: 2,

the nucleic acid sequence encoding a HPV6 E7 antigen comprises nucleotides 1447-1737 of SEQ ID NO: 2 or a nucleic acid sequence having at least 99% identity to nucleotides 1447-1737 of SEQ ID NO: 2, or

any combination thereof.

2 . The nucleic acid molecule according to claim 1 , wherein the nucleic acid sequence encoding the HPV11 E6 antigen and the nucleic acid sequence encoding the HPV11 E7 antigen are located 5′ to the nucleic acid sequence encoding the HPV6 E6 antigen and the nucleic acid sequence encoding the HPV6 E7 antigen.

3 . The nucleic acid molecule according to claim 1 , wherein the nucleic acid sequence encoding the HPV6 E6 antigen and the nucleic acid sequence encoding the HPV6 E7 antigen are located 5′ to the nucleic acid sequence encoding the HPV11 E6 antigen and the nucleic acid sequence encoding the HPV11 E7 antigen.

4 . The nucleic acid molecule according to claim 1 , wherein the nucleic acid sequence encoding the HPV11 E6 antigen and the nucleic acid sequence encoding the HPV11 E7 antigen are separated from the nucleic acid sequence encoding the HPV6 E6 antigen and the nucleic acid sequence encoding the HPV6 E7 antigen by a nucleic acid sequence encoding one or more post-translational cleavage sites, one or more translational skipping sites, or both.

5 . The nucleic acid molecule according to claim 1 , wherein the nucleic acid sequence encoding the HPV6 E6 antigen and the nucleic acid sequence encoding the HPV6 E7 antigen are separated by a nucleic acid sequence encoding one or more post-translational cleavage sites, one or more translational skipping sites, or both.

6 . The nucleic acid molecule according to claim 1 , wherein the nucleic acid sequence encoding the HPV11 E6 antigen and the nucleic acid sequence encoding the HPV11 E7 antigen are separated by a nucleic acid sequence encoding one or more post-translational cleavage sites, one or more translational skipping sites, or both.

7 . An expression vector comprising the nucleic acid molecule according to claim 1 .

8 . The expression vector of claim 7 , wherein the expression vector comprises a DNA plasmid.

9 . A vaccine comprising the expression vector of claim 7 and a pharmaceutically acceptable excipient.

10 . A pharmaceutical composition comprising the expression vector of claim 7 and a pharmaceutically acceptable excipient.

11 . The pharmaceutical composition according to claim 10 , further comprising an adjuvant.

12 . The pharmaceutical composition according to claim 11 , wherein the adjuvant comprises interleukin-12 (IL12), a nucleic acid molecule encoding IL12, a nucleic acid molecule comprising a nucleotide sequence encoding the p35 subunit of IL12, a nucleic acid molecule comprising a nucleotide sequence encoding the p40 subunit of IL12, or a nucleic acid molecule comprising a nucleotide sequence encoding the p35 subunit of IL12 and the p40 subunit of IL12.

13 . The pharmaceutical composition according to claim 12 , wherein the nucleotide sequence encoding the p35 subunit of IL12 comprises a nucleotide sequence selected from the group consisting of:

a nucleotide sequence that encodes SEQ ID NO: 6; or

a nucleotide sequence that is at least 95% identical to a nucleotide sequence that encodes SEQ ID NO: 6.

14 . The pharmaceutical composition according to claim 12 , wherein the nucleotide sequence encoding the p40 subunit of IL12 comprises a nucleotide sequence selected from the group consisting of:

a nucleotide sequence that encodes SEQ ID NO: 8; or

a nucleotide sequence that is at least 95% identical to a nucleotide sequence that encodes SEQ ID NO: 8.

15 . The pharmaceutical composition according to claim 12 , wherein the nucleotide sequence encoding IL12 comprises a nucleotide sequence selected from the group consisting of:

the nucleotide sequence of SEQ ID NO: 4; or

a nucleotide sequence that is at least 95% identical to the nucleotide sequence of SEQ ID NO: 4.

16 . The pharmaceutical composition according to claim 12 , wherein the nucleic acid molecule encoding IL12, the nucleic acid molecule comprising a nucleotide sequence encoding the p35 subunit of IL12, the nucleic acid molecule comprising a nucleotide sequence encoding the p40 subunit of IL12, or the nucleic acid molecule comprising a nucleotide sequence encoding the p35 subunit of IL12 and the p40 subunit of IL12 is an expression vector.

17 . The pharmaceutical composition according to claim 16 , wherein the expression vector comprising the nucleic acid molecule encoding IL12, the nucleic acid molecule comprising a nucleotide sequence encoding the p35 subunit of IL12, the nucleic acid molecule comprising a nucleotide sequence encoding the p40 subunit of IL12, or the nucleic acid molecule comprising a nucleotide sequence encoding the p35 subunit of IL12 and the p40 subunit of IL12 is the same expression vector or a different expression vector than the expression vector comprising the nucleic acid molecule comprising a nucleic acid sequence encoding a HPV11 E6 antigen, a nucleic acid sequence encoding a HPV11 E7 antigen, a nucleic acid sequence encoding a HPV6 E6 antigen, and a nucleic acid sequence encoding a HPV6 E7 antigen.

18 . The pharmaceutical composition according to claim 16 , wherein the pharmaceutically acceptable excipient comprises a buffer.

19 . The pharmaceutical composition of claim 18 , wherein the buffer is a saline-sodium citrate buffer.

20 . The pharmaceutical composition of claim 19 , wherein the composition comprises 6 mg of the expression vector comprising the nucleic acid molecule comprising a nucleic acid sequence encoding a HPV11 E6 antigen, a nucleic acid sequence encoding a HPV11 E7 antigen, a nucleic acid sequence encoding a HPV6 E6 antigen, and a nucleic acid sequence encoding a HPV6 E7 antigen per milliliter of buffer and 0.25 mg of the expression vector comprising the nucleic acid molecule encoding IL12, the nucleic acid molecule comprising a nucleotide sequence encoding the p35 subunit of IL12, the nucleic acid molecule comprising a nucleotide sequence encoding the p40 subunit of IL12, or the nucleic acid molecule comprising a nucleotide sequence encoding the p35 subunit of IL12 and the p40 subunit of IL12, per milliliter of buffer.

21 . A method of inducing an immune response in a subject comprising administering to the subject an effective amount of the pharmaceutical composition according to claim 10 , to thereby induce the immune response.

22 . A method of prophylactically or therapeutically immunizing a subject against HPV6 and/or HPV11 comprising administering to the subject an effective amount of the pharmaceutical composition according to claim 16 to thereby induce an immune response against HPV6, HPV11, or both.

23 . A method for treating or preventing recurrent respiratory papillomatosis (RRP) in a subject comprising administering to the subject an effective amount the pharmaceutical composition according to claim 10 to thereby treat or prevent RRP.

24 . The method according to claim 23 , wherein the RRP is juvenile-onset RRP or adult-onset RRP.

25 . The method according to claim 23 , wherein the administering comprises intradermal or intramuscular injection.

26 . The method according to claim 25 , wherein the administering further comprises electroporation.

27 . The method according to claim 22 , wherein the administering comprises intradermal or intramuscular injection.

28 . The method according to claim 27 , wherein the administering further comprises electroporation.

29 . The method according to claim 21 , wherein the administering comprises intradermal or intramuscular injection.

30 . The method according to claim 29 , wherein the administering further comprises electroporation.

31 . The pharmaceutical composition according to claim 12 , wherein the nucleotide sequence encoding the p35 subunit of IL12 comprises a nucleotide sequence selected from the group consisting of:

the nucleotide sequence of SEQ ID NO: 5; or

a nucleotide sequence that is at least 95% identical to SEQ ID NO: 5.

32 . The pharmaceutical composition according to claim 12 , wherein the nucleotide sequence encoding the p40 subunit of IL12 comprises a nucleotide sequence selected from the group consisting of:

the nucleotide sequence of SEQ ID NO: 7; or

a nucleotide sequence that is at least 95% identical to SEQ ID NO: 7.

33 . The nucleic acid molecule of claim 1 , wherein the nucleic acid sequence encoding a HPV11 E6 antigen comprises nucleotides 1-447 of SEQ ID NO: 2 or a nucleic acid sequence having at least 99% identity to nucleotides 1-447 of SEQ ID NO: 2.

34 . The nucleic acid molecule of claim 1 , wherein the nucleic acid sequence encoding a HPV11 E7 antigen comprises nucleotides 535-825 of SEQ ID NO: 2 or a nucleic acid sequence having at least 99% identity to nucleotides 535-825 of SEQ ID NO: 2.

35 . The nucleic acid molecule of claim 1 , wherein the nucleic acid sequence encoding a HPV6 E6 antigen comprises nucleotides 913-1359 of SEQ ID NO: 2 or a nucleic acid sequence having at least 99% identity to nucleotides 913-1359 of SEQ ID NO: 2.

36 . The nucleic acid molecule of claim 1 , wherein the nucleic acid sequence encoding a HPV6 E7 antigen comprises nucleotides 1447-1737 of SEQ ID NO: 2 or a nucleic acid sequence having at least 99% identity to nucleotides 1447-1737 of SEQ ID NO: 2.

Continuity (3)
Continuation 17320944 · May 14, 2021
Provisional Application 63024912 · May 14, 2020
Related Publication 20230414744A1 · Dec 28, 2023
References Cited (63)
US 3805783A · Ismach · 1974 [cited by applicant]
US 4342310A · Lindmayer et al. · 1982 [cited by applicant]
US 4447223A · Kaye et al. · 1984 [cited by applicant]
US 5505697A · McKinnon et al. · 1996 [cited by applicant]
US 5580859A · Felgner et al. · 1996 [cited by applicant]
US 5676646A · Hofmann et al. · 1997 [cited by applicant]
US 5679647A · Carson et al. · 1997 [cited by applicant]
US 5702359A · Hofmann et al. · 1997 [cited by applicant]
US 5703055A · Felgner et al. · 1997 [cited by applicant]
US 6009347A · Hofmann · 1999 [cited by applicant]
US 6068650A · Hofmann et al. · 2000 [cited by applicant]
US 6096020A · Hofmann · 2000 [cited by applicant]
US 6120493A · Hofmann · 2000 [cited by applicant]
US 6150148A · Nanda et al. · 2000 [cited by applicant]
US 6181964B1 · Hofmann et al. · 2001 [cited by applicant]
US 6192270B1 · Hofmann et al. · 2001 [cited by applicant]
US 6208893B1 · Hofmann · 2001 [cited by applicant]
US 6216034B1 · Hofmann et al. · 2001 [cited by applicant]
US 6233482B1 · Hofmann et al. · 2001 [cited by applicant]
US 6241701B1 · Hofmann · 2001 [cited by applicant]
US 6302874B1 · Zhang et al. · 2001 [cited by applicant]
US 6520950B1 · Hofmann et al. · 2003 [cited by applicant]
US 6763264B2 · Hofmann · 2004 [cited by applicant]
US 7171264B1 · Hofmann et al. · 2007 [cited by applicant]
US 7245963B2 · Draghia-Akli et al. · 2007 [cited by applicant]
US 7328064B2 · Mathiesen et al. · 2008 [cited by applicant]
US 7664545B2 · Westersten et al. · 2010 [cited by applicant]
US 11419925B2 · Weiner et al. · 2022 [cited by applicant]
US 20040175727A1 · Draghia-Akli et al. · 2004 [cited by applicant]
US 20080234655A1 · Mathiesen et al. · 2008 [cited by applicant]
US 20170151320A1 · Weiner · 2017 [cited by examiner]
US 20180179257A1 · Monath et al. · 2018 [cited by applicant]
US 20190062379A1 · Li et al. · 2019 [cited by applicant]
US 20190192650A1 · Weiner et al. · 2019 [cited by applicant]
US 20210353736A1 · Ramos et al. · 2021 [cited by applicant]
US 20220112273A1 · Weiner et al. · 2022 [cited by applicant]
US 20230017972A1 · Fisher et al. · 2023 [cited by applicant]
US 20230023093A1 · Weiner et al. · 2023 [cited by applicant]
JP 2017537621A · 2017 [cited by applicant]
JP 2019115355A · 2019 [cited by applicant]
WO 2014165291A1 · 2014 [cited by applicant]
WO 2019151760A1 · 2019 [cited by applicant]
WO 2021081480A2 · 2021 [cited by applicant]
GenBank: AF180562.1. [cited by examiner]
GenBank: AF180563.1. [cited by examiner]
Oh et al. Roles of the E6 and E7 Proteins in the Life Cycle of Low-Risk Human Papillomavirus Type 11. J. Virol., 2004, 78(5): 2620-2626. [cited by examiner]
Zhang et al. The E7 proteins of low-and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. PNAS, 2006, 103:437-442. [cited by examiner]
Derkay et al.; “A staging system for assessing severity of disease and response to therapy in recurrent respiratory papillomatosis”; Laryngoscope; vol. 108(6); Jun. 1998; p. 935-937. [cited by applicant]
ISA/220—Notification of Transmittal or Search Report and Written Opinion of the ISA, or the Declaration Mailed on Jan. 17, 2024 for WO Application No. PCT/US23/076860, 10 page(s). [cited by applicant]
“INO-3107 With Electroporation (EP) in Participants With HPV-6-and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)”; https://clinicaltrials.gov/ct2/show/NCT04398433; accessed Jun. 3, 2021; 8 pages. [cited by applicant]
Bonagura et al.; “Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and-11”; Journal of Pathology, Microbiology and Immunology; vol. 118; 2010; p. 455-470. [cited by applicant]
Donnelly et al.; “DNA Vaccines”; Annual Review of Immunology; vol. 15; 1997; p. 617-648. [cited by applicant]
GenBank: AAK84425.1. interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 1, p35) [ [cited by applicant]
GenBank: BAJ20855.1. interleukin 12B, partial [synthetic construct]. Dated Jul. 25, 2016. [cited by applicant]
Gissmann et al.; “Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers”; Proc. Natl. Acad. Sci.; vol. 80; Jan. 1983; p. 560-563. [cited by applicant]
Gradishar et al.; “Breast Cancer Version 3.2014”; Nat'l Comprehensive Cancer Network; vol. 12; Apr. 2014; p. 542-590. [cited by applicant]
IPEA/409—International Preliminary Report on Patentability Mailed on Nov. 24, 2022 for WO Application No. PCT/US21/032545. [cited by applicant]
ISA/220—Notification of Transmittal or Search Report and Written Opinion of the ISA, or the Declaration Mailed on Sep. 16, 2021 for WO Application No. PCT/US21/032545. [cited by applicant]
Mounts et al.; “Viral etiology of juvenile-and adult-onset squamous papilloma of the larynx”; Proc. Natl. Acad. Sci.; vol. 79; Sep. 1982; p. 5425-5429. [cited by applicant]
Omland et al.; “Recurrent Respiratory Papillomatosis: HPV Genotypes and Risk of High-Grade Laryngeal Neoplasia”; Plos ONE; vol. 9; Jun. 2014; e99114; 7 pages. [cited by applicant]
Outgoing—ISA/210—International Search Report Mailed on Sep. 16, 2021 for WO Application No. PCT/US21/032545. [cited by applicant]
Schultheis et al.; “Optimized Interferon-gamma ELISpot Assay to Measure T Cell Responses in the Guinea Pig Model after Vaccination”; Journal of Visualized Experiments; vol. 143; Jan. 2019; 7 pages. [cited by applicant]
Winton et al.; “Vinorelbine plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer”; The New England Journal of Medicine; vol. 352; 2005; p. 2589-2597. [cited by applicant]